Current Appointments & Affiliations
Eleanor Easley Distinguished Professor in the School of Medicine
·
2023 - Present
Medicine, Medical Oncology,
Medicine
Professor of Medicine
·
2015 - Present
Medicine, Medical Oncology,
Medicine
Professor in Surgery
·
2015 - Present
Surgery,
Clinical Science Departments
Professor in Urology
·
2025 - Present
Urology,
Clinical Science Departments
Member of the Duke Cancer Institute
·
2003 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
Impact of postprogression therapies on overall survival: Recommendations from the 2023 kidney cancer association think tank meeting.
Journal Article Urol Oncol · March 2025 Modern advances in systemic and localized therapies for patients with renal cell carcinoma (RCC) have significantly improved patients' outcomes. If disease progression occurs after initial treatment, clinicians often have multiple options for a first salva ... Full text Link to item CiteReal-World Evidence of Combination Therapy Use in Metastatic Hormone-Sensitive Prostate Cancer in the United States From 2017 to 2023.
Journal Article JCO Oncol Pract · February 7, 2025 PURPOSE: Treatment of metastatic hormone-sensitive prostate cancer (mHSPC) has evolved with robust clinical trial evidence on the benefits of combining androgen-deprivation therapy (ADT) with androgen receptor pathway inhibitors (ARPIs; abiraterone, apalut ... Full text Link to item CiteManagement of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC).
Journal Article Eur Urol · February 2025 BACKGROUND AND OBJECTIVE: Innovations have improved outcomes in advanced prostate cancer (PC). Nonetheless, we continue to lack high-level evidence on a variety of topics that greatly impact daily practice. The 2024 Advanced Prostate Cancer Consensus Confe ... Full text Link to item CiteRecent Grants
Lutetium Long-term Safety Follow-up study
Clinical TrialPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2023 - 2035A Phase 2, Randomized, Double-blind, Clinical Study of V940 (mRNA-4157) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in the Adjuvant Treatment of Participants With Renal Cell Carcinoma
Clinical TrialPrincipal Investigator · Awarded by Merck Sharp & Dohme · 2024 - 2029Intermittent Fasting using a Fasting-Mimetic Diet to Improve Prostate Cancer Control and Metabolic Outcomes
ResearchCo Investigator · Awarded by Cedars Sinai Medical Center · 2023 - 2028View All Grants
Education, Training & Certifications
Duke University ·
1992
M.D.